Domain Therapeutics, a clinical-stage biopharmaceutical company developing highly differentiated therapeutic strategies targeting G protein-coupled receptors (GPCRs), has appointed Jean-Marie Cuillerot, M.D., as Chief Medical Officer (CMO).

Experience

Based in Boston, Cuillerot brings extensive pharmaceutical and biotech experience, with a proven track record in leading successful clinical development programs and regulatory strategy. Earlier in his career, he served as the medical lead at Bristol-Myers Squibb for the lifecycle management of ipilimumab, the first approved immune checkpoint inhibitor for cancer.

At EMD Serono, an affiliate of Merck Serono, Cuillerot held senior leadership positions as Global Head of Clinical Development in Immuno-Oncology and later as Vice President of Clinical Immunotherapy/Immuno-Oncology. Notably, he directed the clinical development of avelumab from pre-IND through global submissions in record time, an achievement recognized with the prestigious Merck CEO Award.

More recently, Cuillerot served as CMO at Acrivon Therapeutics, Dragonfly Therapeutics, and at Agenus, where his leadership has consistently accelerated the progression of innovative therapies from early clinical stages toward regulatory milestones.

Sean A. MacDonald, CEO of Domain Therapeutics, said: “I am delighted to welcome Jean-Marie to the team. A distinguished industry leader with extensive expertise in the biotechnology and pharmaceutical sector, and a proven track record of leading clinical teams and optimizing clinical strategies, he is ideally positioned to help advance our innovative pipeline toward clinical proof of efficacy, driving our corporate growth.”

Cuillerot said: ” I look forward to collaborating with this talented team to advance these candidates through clinical development and toward a successful market entry. Together, we will drive meaningful innovation that benefits patients and creates lasting value for all our stakeholders.”